placebo for risankizumab + risankizumab IV + risankizumab SC

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Crohn's Disease

Conditions

Crohn's Disease

Trial Timeline

May 10, 2017 → Apr 14, 2021

NCT ID

NCT03105128

About placebo for risankizumab + risankizumab IV + risankizumab SC

placebo for risankizumab + risankizumab IV + risankizumab SC is a phase 3 stage product being developed by AbbVie for Crohn's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03105128. Target conditions include Crohn's Disease.

What happened to similar drugs?

9 of 20 similar drugs in Crohn's Disease were approved

Approved (9) Terminated (4) Active (11)

✅adalimumabAbbVieApproved

✅Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeksMerckApproved

✅Infliximab + Prednisolone + AzathioprinePfizerApproved

✅Celebrex + placeboPfizerApproved

✅Cimzia + MesalamineUCBApproved

✅Certolizumab PegolUCBApproved

✅certolizumab pegol + certolizumab pegol + certolizumab pegol + certolizumab pegolUCBApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03105128	Phase 3	Completed	May 10, 2017	Apr 14, 2021	Crohn's Disease

Competing Products

20 competing products in Crohn's Disease

See all competitors

Product	Company	Stage	Hype Score
CT-P13 + Remicade	Celltrion	Phase 3	40
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13	Celltrion	Phase 1	29
CT-P13 SC (Infliximab)	Celltrion	Phase 3	40
CP-461	Astellas Pharma	Phase 2	35
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kg	Eisai	Phase 1/2	32
E6011 + Placebo	Eisai	Phase 2	35
E6011 + Placebo	Eisai	Phase 1	21
adalimumab + adalimumab + placebo	Eisai	Phase 2/3	38
adalimumab	Eisai	Phase 2/3	38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + Placebo	Eli Lilly	Phase 3	40
Mirikizumab	Eli Lilly	Phase 3	47
Mirikizumab + Mirikizumab + Tirzepatide + Placebo	Eli Lilly	Phase 3	47
Mirikizumab + Placebo	Eli Lilly	Phase 2	35
Mirikizumab	Eli Lilly	Phase 3	44
Matching Placebo for Upadacitinib + Upadacitinib	AbbVie	Phase 3	40
Adalimumab + Placebo	AbbVie	Phase 3	40
Upadacitinib + Placebo for Upadacitinib	AbbVie	Phase 3	40
Placebo + ABT-494	AbbVie	Phase 2	35
ABT-494	AbbVie	Phase 2	35
Risankizumab + Comparator	AbbVie	Pre-clinical	33